E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Vaccination of adult subjects aged 18 to 40 years and elderly subjects aged 60 to 85 years with an inactivated, split-virion influenza vaccine administered via the intradermal route using Vaxigrip® as IM reference vaccine |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To describe the cellular immune response per age group (adults or elderly) and vaccine group (ID influenza or IM comparator vaccines) before vaccination, and, 7 days, 10 days, 14 days, 21 days, 180 days after vaccination - To describe the humoral immune response per age group and vaccine group before vaccination, 14 days, 21 days, and 180 days after vaccination - To describe mucosal immunity per age group and vaccine group through quantification of influenza-specific IgA (total, specific and sub-classes: IgA1 and IgA2) collected from saliva and serum before vaccination and 10 days, 14 days, 21 days and 180 days after vaccination - To describe the safety of the vaccines per age group and per vaccine group after vaccination |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Aged 18 to 40 years (adults) or 60 to 85 years (elderly) 2) Provision of a signed informed consent 3) Able to attend all scheduled visits and comply with all trial procedures 4) For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until 4 weeks after vaccination 5) Entitlement to national social security
|
|
E.4 | Principal exclusion criteria |
1) For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test 2) Breast-feeding woman 3) Participation in another clinical trial investigating a vaccine, drug, medical device or a medical procedure in the 4 weeks preceding the trial vaccination 4) Planned participation in another clinical trial during the present trial period 5) Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy 6) Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances 7) Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator 8) Current alcohol abuse or drug addiction that may interfere with the subject’s ability to comply with trial procedures 9) Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response 10) Receipt of any vaccine in the 4 weeks preceding the trial vaccination 11) Planned receipt of any vaccine in the 4 weeks following the trial vaccination 12) Known Human Immunodeficiency Virus, Hepatitis B or Hepatitis C seropositivity 13) Previous vaccination against Influenza in the previous 6 months 14) Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding the inclusion contraindicating IM vaccination 15) Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent 16) Febrile illness (oral temperature ≥37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Cellular Immune Response
- Intracellular Cytokine Staining (ICS): -- To quantify the number of Interferon- γ (INF-γ), Interleukine-2 (IL-2) or Tumor necrosis factor- α (TNF-α) secreting CD4+ and CD8+ T lymphocytes after stimulation with influenza live virus (for each vaccine strain) in all the subjects at D0, D7, D10, D14, D21 and D180 -- To quantify the number of influenza-specific CD4+ and CD8+ T lymphocytes displaying a memory profile (IL-2 secreting cells [IL-2+]) in all the subjects at D0, D7, D10, D14, D21 and D180 -- To quantify the number of influenza-specific CD4+ and CD8+ T lymphocytes exhibiting an effector profile (INF-γ and TNF-α secreting cells [INF-γ+ and TNF-α+]) in all the subjects at D0, D7, D10, D14, D21 and D180
- Cytometric Bead Array (CBA): -- To measure the concentration of a panel of Th1 (IFN-γ, TNF-α, IL-2), and Th2 (IL-5, IL-4, IL 10) cytokines secreted by peripheral blood mononuclear cells (PBMCs) upon in vitro re stimulation with the three influenza vaccine strains in all the subjects at D0 and at the peak of the cellular response measured by ICS (D7 or D10 or D14 or D21 or D180)
- Lymphoproliferation: -- To quantify the specific lymphoproliferative response (measured by 3H-thymidine incorporated in cells and expressed in counts per minute [cpm]), upon in vitro re-stimulation of PBMCs (= Stimulation Index [SI]) with influenza antigens from the three vaccine strains in all the subjects at D0 and at the peak of the cellular response measured by ICS (D7 or D10 or D14 or D21 or D180) Depending on the results obtained with ICS method, CBA and lymphoproliferation assessments will not be performed at each timepoint: if a peak of response is clearly identified for one of the timepoints tested, CBA and lymphoproliferatrion methods will be performed at this timepoint only. If no peak of response emerged, CBA and lymphoproliferatrion method will be performed at the most relevant timepoint obtained according to results and literature.
Humoral Immune Response
The humoral immune response will be evaluated in all subjects using the hemagglutination inhibition (HI) test. Anti-hemagglutinin (HA) antibody titers for the three strains will be measured before vaccination and at 14, 21, and 180 days after vaccination. The endpoints per strain will be: -- Anti-HA individual titer on D0, D14, D21 and D180 -- Individual titers ratio:, D14/D0, D21/D0 and D180/D0 -- Seroconversion status (subjects with a pre-vaccination titer < 10 [1/dil], post-vaccination titer ≥40 [1/dil] on D14, D21 and D180), or significant increase of post-vaccination titer (subjects with a pre-vaccination titer ≥10 [1/dil], post-vaccination titer ≥ 4-fold increase versus pre- vaccination titer on D14, D21 and D180) --Seroprotection status: titer ≥40 (1/dil) on D14, D21 and D180 Seroprotection and seroconversion will be described using the criteria of the Committee for Human Medicinal Products (CHMP) Note for Guidance (NfG) CPMP/BWP/214/96.
Mucosal Immunity
Total IgA, specific IgA, IgA1 and IgA2, each from saliva and serum, will be measured using Enzyme-Like Immunsorbent Assay (ELISA) before vaccination and 10, 14, 21, and 180 days after vaccination. The endpoints will be: -- Individual titer - for saliva and serum - for Total IgA, Specific IgA, IgA1 and IgA2 on D0, D10, D14, D21 and D180 -- Individual titer ratio - for saliva and serum - for Total IgA, Specific IgA, IgA1 and IgA2 on D10/D0, D14/D0, D21/D0 and D180/D0 Individual titer ratio - for saliva and serum - Specific IgA / Total IgA on D0, D10, D14, D21 and D180
Safety
The endpoints will be: -- Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred term), duration, severity, and relationship to vaccination of any unsolicited systemic adverse events (AEs) reported in the 30 minutes after vaccination -- Occurrence of the reactions (MedDRA Preferred Terms) as per the Committee for Human Medicinal Products (CHMP) NfG CPMP/BWP/214/96 in the 3 days following vaccination. -- Occurrence, time to onset, number of days of occurrence, and severity of solicited (prelisted in the subject’s diary card (DC) and the Case Report Form [CRF]) injection site and systemic reactions up to 7 days after vaccination -- Occurrence, nature (MedDRA preferred term), time to onset, duration, severity, and relationship to vaccination (for systemic AEs only) of unsolicited (spontaneously reported) AEs up to 21 days after vaccination |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
immunogenicity (in terms of cellular, humoral and mucosal immune responses) |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |